Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study.
about
Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patientsBacterial contamination of inanimate surfaces and equipment in the intensive care unitBloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteriaEmpiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patientsPopulation-based epidemiology and microbiology of community-onset bloodstream infectionsT2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasisDoes it Matter if we get it right? Impact of appropriateness of empiric antimicrobial therapy among surgical patients.Characteristics and risk factors for 28-day mortality of hospital acquired fungemias in ICUs: data from the EUROBACT studyWeekly high-dose liposomal amphotericin B (L-AmB) in critically ill septic patients with multiple Candida colonization: The AmBiDex study.Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study.Diagnosis and management of temperature abnormality in ICUs: a EUROBACT investigators' survey.Ventilator-associated tracheobronchitis: where are we now?Risk of bloodstream infection in children admitted to paediatric intensive care units in England and Wales following emergency inter-hospital transfer.The clinical characteristics, carbapenem resistance, and outcome of Acinetobacter bacteremia according to genospecies.Epidemiology and microbiology of nosocomial bloodstream infections: analysis of 482 cases from a retrospective surveillance study.Treatment of bloodstream infections in ICUsClinical and microbiological characteristics of bloodstream infections due to AmpC β-lactamase producing Enterobacteriaceae: an active surveillance cohort in a large centralized Canadian region.Management of invasive candidiasis in nonneutropenic ICU patients.Sepsis Pathogen Identification.How to treat fungal infections in ICU patients.Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data.Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study.Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study.Year in review in Intensive Care Medicine 2012. II: Pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues.Bloodstream infections in the Intensive Care Unit.Copper Resistance of the Emerging Pathogen Acinetobacter baumanniiEpidemiology of Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the carbapenem resistance and patient mortality.How to measure the impacts of antibiotic resistance and antibiotic development on empiric therapy: new composite indices.Nosocomial infections after severe trauma are associated with lower apolipoproteins B and AII.Invasive fungal infections in the ICU: how to approach, how to treat.Year in review in Intensive Care Medicine 2013: III. Sepsis, infections, respiratory diseases, pediatrics.Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria.Nosocomial Candidiasis: Antifungal Stewardship and the Importance of Rapid Diagnosis.The Role of Adjunctive Therapies in Septic Shock by Gram Negative MDR/XDR Infections.The use and risks of antibiotics in critically ill patients.Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study.Managing the oncologic patient with suspected pneumonia in the intensive care unit.Understanding why resistant bacteria are associated with higher mortality in ICU patients.Prophylaxis for Stress Ulcers With Proton Pump Inhibitors Is Not Associated With Increased Risk of Bloodstream Infections in the Intensive Care Unit.The current treatment landscape: candidiasis.
P2860
Q26751621-7C0047FB-7FB2-4266-ADE5-76A91B667864Q26773771-0656B268-1648-4687-A0DE-7362DCD7192EQ26795565-E3894961-0BE0-43A1-863E-01A89D673EE5Q26852351-1D691012-BF8F-46DE-9F59-012F7B5C07DEQ27013639-7592AFFC-9A1B-47FA-B22B-9F44AFC94D27Q28084998-A02AA560-C399-477E-ADBE-6E589A7EF357Q28392467-D34F594F-07BE-4855-B6ED-CC860C230248Q31054881-ACB01D96-4147-4E89-A6BE-3F7C6066909FQ33712955-E46E51F6-8204-4F74-AE61-68C2D6612C47Q33754099-E0511BC4-E80A-49AA-A5F8-5ACD5DD63C32Q33754287-2DD38A59-E05C-4121-93A2-3EA8FD11B28AQ34301010-D49DDD7F-62B5-4DD2-B08B-95403EEBA66EQ34553557-353911E7-BA0A-4160-8B11-82F2693BA057Q34766027-9A333932-4BC1-40B3-B423-96DBD9DFF60AQ34890664-1672035E-C868-440C-B851-441BB05F0A72Q34896896-888F7C94-8EB6-4612-AFED-A7B47ADF1E43Q34987739-242EE90F-5783-499B-A78F-0E804A54C22DQ35122093-A6A12BF8-DF8B-4F5C-9895-47EC3C540B29Q35550946-9126CA24-5773-4288-A0B4-19B621316543Q35568846-BA1DCCA9-4710-418E-994B-ADC23993FE3FQ35775400-81BF0A2A-D023-4392-A9BD-38AE229F7DAAQ36257873-0B04837A-BF09-4918-918D-C0CE9C016011Q36441468-90D943B0-CD45-4512-B641-96CB477CFCB2Q36627891-411ABA41-511E-4316-BB9A-696E777757F3Q36913336-DD0EB6CC-FF96-46CB-B80F-66C2BB3A13EFQ37346473-C341A948-0E9B-4814-A30E-7702E834B17DQ37422089-EA889C77-7E8B-4422-96B5-7C284F03520DQ37517286-C7CC1FD3-CD72-42A9-8E4E-47919F608632Q37555546-01D1B7FE-183E-4074-91D5-8CD8E339F55DQ38180287-42BD45D5-4A9C-47A0-B4C7-630D62F00ECDQ38187368-126E618C-1053-4279-BE19-8621F2CD97F6Q38384662-AE38789B-4F0D-4EAB-ADF7-60DD30FD784EQ38589279-BDF0BFE9-8072-4345-A4DD-627A82FF4F33Q38642048-C9DB643D-BD0E-4C83-BFE4-D1FCF3BF88A4Q38767901-91044DB5-5304-4BAF-9A1E-0946A2E8069DQ38861673-EC0BA901-3FBF-4F32-9896-9B6F2167A070Q38940456-9FB572BC-CA2C-445E-909B-2D3C6AFDFC2AQ38943190-7E4A1579-B967-4410-98B2-C0E401D36C9DQ39007578-52D4B5C4-16A3-4870-AA5E-0F9AAC3B32B0Q39018200-52ACDBA8-DE6A-41E2-BDA5-59372A1FEFF6
P2860
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Characteristics and determinan ...... CT International Cohort Study.
@en
Characteristics and determinan ...... CT International Cohort Study.
@nl
type
label
Characteristics and determinan ...... CT International Cohort Study.
@en
Characteristics and determinan ...... CT International Cohort Study.
@nl
prefLabel
Characteristics and determinan ...... CT International Cohort Study.
@en
Characteristics and determinan ...... CT International Cohort Study.
@nl
P2093
P2860
P50
P1476
Characteristics and determinan ...... CT International Cohort Study.
@en
P2093
Adam Mikstacki
Akos Csomos
Aurélien Vesin
Benoit Misset
Claude Martin
Frederico Bruzzi de Carvalho
Georges Dimopoulos
Jean Carlet
Jean-François Timsit
Jean-Ralph Zahar
P2860
P2888
P304
P356
10.1007/S00134-012-2695-9
P50
P577
2012-09-26T00:00:00Z